From Wikipedia, the free encyclopedia
Antiviral drug
Pharmaceutical compound
Galidesivir Legal status
(2S ,3S ,4R ,5R )-2-(4-Amino-5H -pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol
CAS Number PubChem CID ChemSpider UNII Formula C 11 H 15 N 5 O 3 Molar mass −1 3D model (JSmol )
O[C@H]3[C@H](c2c1ncnc(N)c1[nH]c2)N[C@H](CO)[C@H]3O
InChI=1S/C11H15N5O3/c12-11-8-6(14-3-15-11)4(1-13-8)7-10(19)9(18)5(2-17)16-7/h1,3,5,7,9-10,13,16-19H,2H2,(H2,12,14,15)/t5-,7+,9-,10+/m1/s1
Key:AMFDITJFBUXZQN-KUBHLMPHSA-N
Galidesivir (BCX4430 , immucillin-A ) is an antiviral drug , an adenosine analog [ 1] nucleoside analog ).[ 2] BioCryst Pharmaceuticals with funding from NIAID , originally intended as a treatment for hepatitis C , but subsequently developed as a potential treatment for deadly filovirus infections such as Ebola virus disease and Marburg virus disease , as well as Zika virus .[ 3] phase 1 human trial in Brazil for coronavirus .[ 4]
It also shows broad-spectrum antiviral effectiveness against a range of other RNA virus families, including bunyaviruses , arenaviruses , paramyxoviruses , coronaviruses , flaviviruses , and phleboviruses .[ 5] [ 1] Ebola virus epidemic in West Africa .[ 6]
Galidesivir later showed efficacy against Zika virus in a mouse model.[ 7]
Galidesivir abrogates viremia in Zika virus–infected rhesus Macaques.[ 8]
Galidesivir is one of several antiviral drugs being tested for coronavirus disease 2019 .[ 9]
On April 9, 2020, BioCryst opened enrollment into a randomized, double-blind, placebo -controlled clinical trial to assess the safety, clinical impact and antiviral effects of galidesivir in patients with COVID-19 .[ 4]
^ a b Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, et al. (April 2014). "Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430" . Nature . 508 (7496): 402–405. Bibcode :2014Natur.508..402W . doi :10.1038/nature13027 . PMC 7095208 PMID 24590073 . ^ Kamat SS, Burgos ES, Raushel FM (October 2013). "Potent inhibition of the C-P lyase nucleosidase PhnI by Immucillin-A triphosphate" . Biochemistry . 52 (42): 7366–7368. doi :10.1021/bi4013287 . PMC 3838859 PMID 24111876 . ^ BioCryst Pharmaceuticals, Inc. (June 10, 2020). "Galidesivir Stops Zika Viral Replication in Primate Model" . GlobeNewswire News Room (Press release). ^ a b Clinical trial number NCT03891420 ClinicalTrials.gov
^ Westover JB, Mathis A, Taylor R, Wandersee L, Bailey KW, Sefing EJ, et al. (August 2018). "Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters" . Antiviral Research . 156 : 38–45. doi :10.1016/j.antiviral.2018.05.013 . PMC 6035881 PMID 29864447 . ^ Rodgers P (8 April 2014). "BioWar Lab Helping To Develop Treatment For Ebola" . Forbes Magazine . ^ Julander JG, Siddharthan V, Evans J, Taylor R, Tolbert K, Apuli C, et al. (January 2017). "Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model" . Antiviral Research . 137 : 14–22. doi :10.1016/j.antiviral.2016.11.003 . PMC 5215849 PMID 27838352 . ^ Lim SY, Osuna CE, Best K, Taylor R, Chen E, Yoon G, et al. (June 2020). "A direct-acting antiviral drug abrogates viremia in Zika virus-infected rhesus macaques" . Science Translational Medicine . 12 (547). doi :10.1126/scitranslmed.aau9135 . PMC 7370316 PMID 32522808 . ^ Duddu P (19 February 2020). "Coronavirus outbreak: Vaccines/drugs in the pipeline for Covid-19" . clinicaltrialsarena.com . Archived from the original on 19 February 2020. Retrieved 19 February 2020 .
